Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in Acute Cerebral Venous Thrombosis
NCT07801638Recruiting
- Sponsor
- Capital Medical University
- Start
- Mar 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Randomised, double-blind trial of tocilizumab in Cerebral venous thrombosis (CVT) (2 arms), sponsored by Capital Medical University. Primary endpoint: Modified Rankin Scale at 1 month. Started Mar 2025; status: recruiting.
02
Drugs
tocilizumab
03
Conditions
Cerebral venous thrombosis (CVT)
Beyond the preview
Go deeper on NCT07801638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07801638.